Nuwellis, Inc. (NUWE) 2024 Annual Report Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2024. Nuwellis, Inc. is a commercial-stage medical technology company focused on the Aquadex System, an ultrafiltration therapy device used to treat fluid overload in patients with heart failure, critical care needs, and pediatric conditions. The company operates as a single reporting segment. In February 2025, following the filing of this report, the company announced the retirement of its CEO and the appointment of an interim CEO.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 |
|---|---|---|
| Net Sales | $8.74 million | $8.86 million |
| Gross Profit | $5.68 million | $4.98 million |
| Gross Margin | 64.9% | 56.2% |
| Operating Loss | $(10.99) million | $(17.63) million |
| Net Loss | $(11.17) million | $(20.21) million |
| Cash and Cash Equivalents | $5.10 million | $3.80 million |
| Accumulated Deficit | $(298.8) million | $(287.6) million |
| Operating Cash Flow | $(9.59) million | $(17.94) million |
Material Changes vs. Prior Period
- Revenue: Net sales decreased 1.4% to $8.74 million, driven by lower console and international sales, partially offset by a 7% increase in circuit sales and a one-time gain from a settlement with SeaStar Medical.
- Profitability: The operating loss narrowed significantly by 37.7% to $10.99 million, primarily due to a 21.7% reduction in SG&A expenses and a 40.8% reduction in R&D expenses.
- Gross Margin: Improved to 64.9% from 56.2% due to higher manufacturing volumes of circuits and lower fixed overhead, despite a $150,000 non-recurring recall expense.
- Financing Activity: The company raised capital through multiple equity offerings in 2024 (April, July, August) and a warrant inducement in November, resulting in $11.0 million of net cash provided by financing activities.
- Stock Structure: A 1-for-35 reverse stock split was effected in June 2024 to regain compliance with Nasdaq listing requirements.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The company has raised substantial doubt about its ability to continue as a going concern. Management believes existing capital resources are sufficient only through May 31, 2025. Additional capital is required to fund operations beyond this date.
- Product Recall: In December 2024, the company issued a Class 1 voluntary recall of specific lots of the AquaFlexFlow UF 500 Plus blood circuit due to mismatch alarms that could lead to patient dehydration. Five incidences were reported, three resulting in patient dehydration.
- Internal Controls: Management identified two material weaknesses in internal control over financial reporting as of December 31, 2024, related to insufficient headcount for segregation of duties and lack of contemporaneous documentation for controls.
- Clinical Pipeline: The REVERSE-HF randomized controlled trial is ongoing with 155 patients enrolled as of February 2025. A dedicated pediatric CRRT device ("Vivian") is in development, with FDA IDE submission expected in Q3 2026.
- Customer Concentration: The ten largest customers represented 49.4% of 2024 revenue, with the single largest customer accounting for 14.4%.
Investor Verification Checklist
- Liquidity Runway: Verify the company's ability to secure additional financing before May 31, 2025, given the "substantial doubt" going concern warning.
- Recall Impact: Assess the financial and reputational impact of the Class 1 blood circuit recall and any potential liability or lost sales.
- Internal Controls: Monitor the remediation plan for the identified material weaknesses in financial reporting controls.
- Customer Concentration: Evaluate the risk associated with the top 10 customers representing nearly 50% of revenue.
- Dilution Risk: Review the terms of outstanding warrants (over 5.3 million shares) and convertible preferred stock, which pose significant dilution risk upon exercise or conversion.